CTRI/2012/10/003064已完成3 期
A Randomized, Double-Blind, Placebo-Control Study to Evaluate Efficacy and Safety of a Novel Enoki Mushroom (Flammulina Velutipes Sing, Chitoglucan Extract) on Weight Management in Healthy Volunteers
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Male or female subjects between 21 to 45 years of age.
- •2 Subject with BMI range (26-32).
- •3 Ability to understand the risks/benefits of the protocol.
- •4 Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera ®, or double-barrier and have a negative pregnancy test at the Screening Visit. Female subjects of non childbearing potential must be amenorrheic for at least 1 years or had a hysterectomy and/or bilateral oophorectomy.
- •5 Willingness to participate in a walking-exercise program (5 days a week, 30 min per day) with the scheduled timing per week during the course of the study
- •6 Subject agrees to consume a vegetarian/non-vegetarian diet of approximately 2,000 kcal/day (17% protein, 25% Fat and 58% carbohydrate)
- •Subject should be available for duration of study period (6-8 months)
- •7 Subject using other therapies for weight management including physiotherapy/ occupational therapy agrees to discontinue these therapies during this study
- •8 Subject agrees not to start any new therapies for weight loss during the course of the study
- •9 Subjects agree to maintain the activity dairy
- •10 Willing to give written informed consent and willing to comply with trial protocol
排除标准
- •1 Subjects suffered from intractable obesity, had defined weight limits or had experienced any recent, unexplained weight loss or gain
- •2 Subjects having history of underlying inflammatory arthropathy, septic arthritis, inflammatory joint disease, gout, pseudogout, Pagets disease, joint fracture, acromegaly, fibromyalgia, Wilsons disease, ochronosi, haemochromatosis, heritable arthritic disorder or collagen gene mutations or rheumatoid arthritis
- •3 Subjects having history of asthma
- •4 Subjects having history of cardiovascular diseases
- •5 Subjects having history of diabetes (Type I or Type II) except other than the subject having the pre-diabetes condition with the fasting blood glucose between 100 to 125 mg/dl or random blood glucose >= 140-199 mg/dl.
- •6 Subject with hyperuricemia (males 480 µmol/L, females 450 µmol/L)
- •7 Subjects having thyroid disease
- •8 Subjects having abnormal liver or kidney function test (ALT or AST 2 times the upper limit of normal; elevated creatinine, male 125 µmol/L, female 110 µmol/L)
- •9 Subjects having abnormal findings on complete blood count
- •10 Subjects having history of coagulopathies
- •11 Subjects with hypertension
- •12 Subjects with HIV Positive
- •13 Subjects having history of congestive heart failure
- •14 Subjects having history high alcohol intake (2 standard drinks per day)
- •15 Pregnant, breast feeding or planning to become pregnant during the study
- •16 Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent
- •17 Any other condition that, in the opinion of the investigator, would adversely affect the subjects ability to complete the study or its measures
- •18 Subjects participated in any investigational study medication within thirty (30) days prior to screening
研究者
相似试验
已完成
不适用
To evaluate Efficacy and Safety of proprietary Herbal Formulation for Weight Management in Healthy VolunteersCTRI/2014/07/004727aila Nutraceuticals
已完成
不适用
To evaluate Efficacy and Safety of proprietary Herbal Formulation for Weight Management in Healthy VolunteersCTRI/2015/06/005835aila Nutraceuticals
已完成
2 期
A double blind clinical Study to Evaluate Efficacy and Safety of a novel formulation on Weight Management in Healthy VolunteersCTRI/2013/08/003891Iovate Health Sciences International Inc100
招募中
1 期
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)Pruritus associated with Primary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-505764-11-00Mirum Pharmaceuticals Inc.395
进行中（未招募）
1 期
A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary sclerosing cholangitisPruritus associated with Primary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2020-003027-41-DEMirum Pharmaceuticals, Inc.300